Description

AstraZeneca: Can Dapagliflozin-Based Combos Unlock a $5 Billion Opportunity in Heart and Kidney Care?

AstraZeneca has reported robust financial and operational performance for the full year and fourth quarter of 2025, showcasing strong growth driven by its diversified product portfolio and significant advancements in its pipeline. The company reported an 8% increase in total revenue, amounting to $25.6 billion, with product revenue growing by 10%, demonstrating strong demand for its innovative medicines across various segments. Core earnings per share (EPS) grew by 11%, reflecting solid profitability. On the product front, AstraZeneca’s oncology segment exhibited significant success, with notable performers including Tagrisso, Imfinzi, and Calquence, achieving substantial year-over-year revenue growth. Enhertu and Datroway also showed impressive advancements. The company’s pipeline demonstrated compelling progress with over 100 Phase III trials underway and expectations of around 20 readouts in 2026. The TroP2 ADC Datroway and new readouts for Imfinzi combinations are set to potentially drive future growth.